What causes cell death in Parkinson's disease?
Currently, there is no proven neuroprotective or neurorestorative therapy for Parkinson's disease (PD). Several advances in the genetics of PD have created an opportunity to develop mechanistic-based therapies that hold particular promise for identifying agents that slow and even halt the progression of PD, as well as restore function. Here we review many of the advances in the last decade regarding the identification of new targets for the treatment of PD based on understanding the molecular mechanisms of how mutations in genes linked to PD cause neurodegeneration.
Gupta
Amitabh
A
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Dawson
Valina L
VL
Dawson
Ted M
TM
D000818:Animals; D016923:Cell Death / Q000235:genetics* / Q000502:physiology; D006801:Humans; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D009154:Mutation; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010300:Parkinson Disease / Q000235:genetics* / Q000473:pathology* / Q000503:physiopathology / Q000628:therapy; D017346:Protein Serine-Threonine Kinases / Q000235:genetics; D051844:alpha-Synuclein / Q000235:genetics
D018696:Neuroprotective Agents; D051844:alpha-Synuclein; C495280:LRRK2 protein, human; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D017346:Protein Serine-Threonine Kinases